The ability to manipulate images with digital mammography can result in fewer callbacks, and breast imaging centers could reduce costs associated with scheduling new appointments, reregistering patients, and rereviewing mammography exams.
The ability to manipulate images with digital mammography can result in fewer callbacks, and breast imaging centers could reduce costs associated with scheduling new appointments, reregistering patients, and rereviewing mammography exams.
Callbacks can result from technical reasons, such as poor patient positioning or patient movement, and from possible or definite abnormalities seen on the exam.
The use of digital mammography at Brigham and Women's Hospital resulted in significantly fewer callbacks of both types, according to a study presented Tuesday at the American Roentgen Ray Society meeting.
For patients, fewer callbacks reduce absenteeism, potential child care costs, and the anxiety associated with being asked to return, said coauthor Dr. Elisabeth Pepperell Frost, a staff radiologist at BWH.
The hospital switched from screen-film to digital mammography in 2003. Investigators led by Dr. Sughra Raza retrospectively reviewed callback rates from pre- and post-digital era.
During one six-month period, the callback rate for 6189 conventional screen-film mammograms was 4.4%. The callback rate for 6792 digital exams during a similar six-month stretch was 3.2%. The difference was significant, Frost said.
Technical improvements in the quality of the exam and the ability to manipulate digital views contributed to fewer callbacks. Specifically, digitally magnifying images reduced the need bring patients back for magnification views.
Most callbacks for digital exams resulted from actual abnormalities seen on the exam, rather than from technical reasons.
For more information from the online Diagnostic Imaging archives:
Digital mammography wins over lingering skeptics
Debate intensifies over clinical superiority of digital systems
Digital mammography delivers rapid results
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.